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Coxsackievirus A-16 (CVA-16) is the agent of hand, 
foot, and mouth disease in children. We report a case of 
fatal pneumonitis in an adult due to a CVA-16 strain with a 
low (78.6%) rate of sequence homology with the reference 
strain. A modiﬁ  ed, more virulent, strain of CVA-16 could be 
emerging.
H
and, foot, and mouth disease (HFMD) is a benign 
condition caused by coxsackievirus A type 16 (CVA-
16), which affects young children and usually resolves un-
eventfully. Rarely, it may be associated with complications 
such as meningitis, encephalitis, myelitis, and respiratory 
failure. During outbreaks of enterovirus infection, respira-
tory failure has been associated with cardiac failure in chil-
dren infected with enterovirus 71 (EV 71) but not in those 
infected with CVA-16 (1,2). We report a case of CVA-16 
pneumonitis that was fatal for an adult.
The Case
In April 2006, a 76-year-old man was admitted to the 
emergency department of Pontchaillou University Hospital, 
Rennes, France, with acute onset of fever, lumbar pain, and 
dyspnea. Examination found a temperature of 37.9°C and 
bilateral pulmonary crackles. Laboratory results were the 
following: leukocytes 9,600 cells ×106/L (90.6% neutro-
phils), C-reactive protein 216 mg/L (normal value <5 mg/
L), and arterial oxygen partial pressure 67 mm Hg (room 
air). Chest radiograph was unremarkable, and Legionella 
pneumophila urinary antigen was not found. The patient 
was treated with amoxicillin-clavulanate and oﬂ  oxacin. 
On day 3, acute respiratory distress syndrome developed, 
and the patient required mechanical ventilation. Computed 
tomographic scan of the thorax showed bilateral alveolo-
interstitial inﬁ   ltrates (Figure). Transthoracic echocardio-
graph and pulmonary artery catheterization showed normal 
left ventricular function. Serum troponin levels were within 
normal limits. 
A bronchoalveolar lavage (BAL) was performed; no 
pyogenic bacteria, L. pneumophila,  Mycobacterium tu-
berculosis, Pneumocystis jiroveci, or Aspergillus sp. were 
isolated despite appropriate staining for direct examination 
and cultures on appropriate media. Negative results were 
obtained in M. tuberculosis PCR and immunoﬂ  uorescence 
assays (IFAs) for P. jiroveci and L. pneumophila. The re-
sult of a PCR for human herpesviruses, which used herpes 
consensus identiﬁ  cation, was negative. Results of testing 
for respiratory syncytial virus, inﬂ  uenza virus, parainﬂ  u-
enza virus, and adenovirus by IFA and ELISA, which used 
speciﬁ  c monoclonal antibody, were all negative. In addi-
tion, serologic test results for L. pneumophila, Mycoplasma 
pneumoniae, Chlamydophila pneumoniae, C. psittaci, Cox-
iella burnetti, and HIV were negative. Three sets of blood 
cultures taken at the time of hospital admission remained 
sterile. Test results for antinuclear factors, antiglomerular 
basement-membrane antibodies, and antineutrophil cyto-
plasmic antibodies were negative.
BAL was positive in 2 enteroviral PCR assays that 
used EV1 primer from Rotbart et al. (3) and real-time PCR 
with primers and probe adapted from Verstrepen et al. (4). 
In addition, on day 3, MRC-5 cell culture showed a speciﬁ  c 
cytopathic effect, which was conﬁ  rmed as enterovirus by 
indirect IFA that used enterovirus mouse monoclonal anti-
body (Novocastra, Newcastle, UK) and ﬂ  uorescein isothio-
cyanate–conjugated Afﬁ  niPure Goat Anti-Mouse (Jackson 
Immuno-Research, West Grove, PA, USA). Enterovirus 
was also detected in serum and pharyngeal samples by 
real-time PCR. Results of real-time PCR and cell culture 
(MRC-5 and LLC-MK2) were also positive for enterovirus 
on BAL performed on days 8 and 14. Kinetics analysis in 
real-time PCR showed a 100-fold decrease in viral load by 
comparison of cycle thresholds between day 8 and day 14 
BAL. Serologic testing for enterovirus showed an 8-fold 
increase in enterovirus antibody titration by complement 
ﬁ  xation between days 3 and 11. Immunoglobulin M to 
echovirus/coxsackievirus was detected by ELISA in serum 
on day 11 (Genzyme, Virotech, Chilly Mazarin, France). 
No drug is currently approved for the treatment of en-
terovirus infection. Pleconaril may be of value in severe 
enteroviral infections (5) but is no longer available because 
licensure was not pursued. The patient did not improve 
and died on day 28 of intractable hypoxemia. Histologic 
examination of postmortem pulmonary biopsy specimen 
showed diffuse alveolar damage and ﬁ  brosis,  real-time 
PCR detected enterovirus, and viral cultures were negative. 
The enterovirus isolated on the day-3 BAL was identiﬁ  ed 
as CVA-16 by partial sequencing of the VP1 region that 
encompasses the BC loop. This region was ampliﬁ  ed with 
primers 292 as sense primer and 222 as antisense primer 
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(6). The sequences obtained (reference no. bankit 845096-
DQ993173 until deﬁ  nitive number assigned) were aligned 
with the corresponding region in GenBank. Comparison of 
a 338-nt sequence with that of the CVA-16 reference strain 
(prototype BrCr) and the EV 71 reference strain (proto-
type G-10) showed nucleotide identity rates of 78.6% and 
64.6%, respectively.
On subsequent questioning, the patient’s wife reported 
that he had had close contact with his granddaughter, who 
had active HFMD, while in the United Kingdom during 
the week before he was admitted. Although a large HFMD 
outbreak occurred in the United Kingdom in 1994 (7), no 
enterovirus outbreaks had been reported at the time of the 
patient’s admission. During the 1994 UK outbreak, CVA 
was isolated in 28 of 40 patients (type CVA-16 in 21 pa-
tients and CVA-10 in 7 patients), but secondary cases in 
family members were rare and no case of pneumonitis or 
death was reported.
Conclusions 
Fatal CVA-16 infection has been described infrequent-
ly in children who had HFMD associated with myocarditis 
(8). We report a fatal CVA-16 infection associated with 
pneumonitis in an adult; to our knowledge, this is the ﬁ  rst 
such report. Our patient had neither myocarditis nor left 
ventricular dysfunction, as demonstrated by pulmonary 
artery catheterization results, echocardiograph results, and 
serum troponin levels. In 2003, 7 fatal cases of HFMD in 
children were reported in Singapore (9). These children 
had interstitial pneumonitis, either alone or associated with 
myocarditis or encephalitis. EV 71 was isolated in 4 cases 
and echovirus 16 in 1. The CVA-16 strain isolated from 
our patient had a low percentage of nucleotide identity 
with the reference strain (78.6%); a threshold of 90% is 
usually required to deﬁ  ne strain homology. This may be a 
sign that this virus is evolving. A strain similar to that from 
our patient was circulating in China from 1999 through 
2004 (98% nucleotide identity; GenBank accession no. 
AY821798) and was isolated from fecal samples of chil-
dren with HFMD or suspected enterovirus infection (10). 
This strain was associated with local yearly outbreaks in 
which only a few cases of neurologic disease and no deaths 
were reported. According to phylogenetic analysis based 
on VP4 207-bp nucleotide sequence, the authors concluded 
that 3 genetic lineages were circulating in Asia at that time 
and suggested that the same tendency may apply in other 
continents (10). 
We report what we believe to be the ﬁ  rst case of CVA-
16 pneumonitis in an adult, with fatal outcome. Preliminary 
sequence analysis revealed a low rate of homology between 
the CVA-16 strain we isolated and those previously pub-
lished, which suggests that a new, more virulent, strain of 
CVA-16 could be emerging. To compare the sequences to 
those published in GenBank, we are sequencing the com-
plete part of the genome encoding the VP1 capsid protein.
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